CASE REPORT

Struma ovarii: two case reports of a rare teratoma of the ovary

Obed Rockson1,*, Christine Kora2, Abdelbassir Ramdani1, Aabdi Basma3, Tariq Bouhout1, Badr Serji1 and Tijani El Harroudi1

1Department of Surgical Oncology, Mohammed VI University Hospital, Regional Oncology Center, Oujda, Morocco, 2Department of Radiology, Mohammed VI University Hospital, Oujda, Morocco and 3Department of Oncology, Mohammed VI University Hospital, Regional Oncology Center, Oujda, Morocco

*Correspondence address. Department of Surgical Oncology, Mohammed VI University Hospital, Regional Oncology Center, Log La colline 3E AP 17 B54, Oujda 60000, Morocco. Tel: (00212) 68056868; E-mail: onnifer1@gmail.com

Abstract

Struma ovarii is an extremely rare type of ovarian teratoma distinguished by the unusual presence of thyroid tissue. It is usually a benign condition; however, malignant transformation is sometimes detected. The diagnosis relies on histopathological examination and is infrequently made on routine investigations. We report two cases of struma ovarii: one benign and the other malignant. The first case involved a 27-year-old woman who underwent a right ovarian cystectomy for an incidental ultrasonographic finding of a solid right adnexal mass. The diagnosis of a benign struma was made after histopathological study. The second case involved a 68-year-old woman who underwent a right salpingo-oophorectomy for a right ovarian bulky mass and the histopathological diagnosis was consistent with that of a malignant struma. We examine the challenges involved in the diagnosis and management of this rare entity.

INTRODUCTION

Struma ovarii (SO) is a rare ovarian teratoma composed entirely or predominantly of thyroid tissue. The immense majority are benign, and ~5% are malignant [1]. It often presents with nonspecific symptoms and can mimic ovarian malignancy. The diagnosis is usually a surprise made after surgery, based on histopathological findings. Treatment of malignant SO is poorly codified due to the rarity of the tumor [2]. We report two cases of SO, discussing its clinicopathological features, diagnostic criteria and management strategies.

CASE REPORTS

Case 1

A 27-year-old nulligravida patient was referred to our hospital for an incidental ultrasonographic finding of a right-solid adnexal mass. She had no history of ovarian or thyroid disease. Physical examination revealed slight abdominal distension with no palpable pelvic mass or signs of ascites. The serum tumor marker, cancer antigen (CA)-125, was slightly increased at 4 IU/ml (reference value < 35 IU/ml). Her pregnancy test was negative. Pelvic
ultrasound revealed a right-solid cystic ovarian mass measuring $2.5 \times 5.0 \times 8.0$ cm with intracystic vegetations (Fig. 1).

Exploratory laparotomy by a Pfannenstiel incision found a multiloculated complex right- cystic ovarian mass. The left ovary and the rest of the abdomen appeared to be free of disease. Subsequently, a right ovarian cystectomy was performed (Fig. 2). Her postoperative course was uneventful and was discharged on day 2. Histopathological analysis of the surgical specimen revealed a cystic wall with thyroid follicles containing irregular and encapsulated colloid, confirming the diagnosis of a benign SO. Eight months of follow-up with ultrasonography and CA-125 at regular intervals has shown no evidence of recurrence.

**Case 2**

A 68-year-old postmenopausal multiparous (parity 5) patient with a medical history of hypertension was referred to our hospital for pelvic pains and progressively increasing abdominal mass over 3 months. Physical examination revealed a voluminous abdominopelvic mobile mass with dullness in the flanks. A contrast computerized tomography (CT) scan revealed a large right-solid cystic adnexal tumor measuring $120 \times 110$ mm with peritoneal carcinosis and left inguinal lymph node metastasis (Fig. 3).

Biological results showed a slight increase in the level of CA-125 at 41 IU/ml. Exploratory laparotomy found a bulky right ovarian mass associated with gelatinous ascites and localized peritoneal carcinosis. The left ovary was free of disease, so a right salpingo-oophorectomy was performed (Fig. 4). She recovered well after surgery and was discharged on day 3. The anatomicopathological study revealed a thyroid papillary carcinoma on an ovarian teratoma with multilocular mucinous cystadenoma, consistent with the diagnosis of a malignant SO (Fig. 5A and B).

Additional cervical ultrasound showed a small homogeneous goiter with two small lymph nodes under the right digastric muscle. The patient showed no signs or symptoms of hyperthyroidism, and the hormonal thyroid function test was normal. After discussion in a multidisciplinary team meeting, the choice of therapies was presented and discussed with the patient. She was offered a total abdominal hysterectomy (TAH) with left contralateral salpingo-oophorectomy, lymphadenectomy and total thyroidectomy, followed by $131I$ radio-ablation, which she refused.

**DISCUSSION**

SO is a rare tumor accounting for 2.7% of all ovarian teratomas and 1% of all ovarian tumors [2, 3]. It occurs mostly in adults
thyroid tissue containing abundant blood vessels and fibrous portions take up the contrast product corresponding to the partitions and multiple cysts with solid components. The solid include a large complex multilobulated mass with thickened and often suspect of malignancy. Common radiological features ultrasound, CT and magnetic resonance imaging are nonspecific value in diagnosis. The different imaging modalities including component (mucous and gelatinous content) [2, 6]. A microscopic appearance is that of a large solid tumor with a mixed histopathological findings of the resected ovary. Gross macroscopic sample reveals a mature teratoma with thyroid tissue. For a teratoma to be categorized as SO, it must contain thyroid tissue [4]. The pure form is seen as the inclusions of thyroid follicles containing colloid, and the mixed form is associated with other malignant tumors including mucinous cystadenocarcinoma, Brenner tumor, carcinoid tumor and malignant melanoma [4, 7]. The criteria for histopathological diagnosis of malignant SO remain controversial and have varied over the years. The reported rates of malignant transformation range from 5 to 37% [6]. Devane et al. [6] concluded that the diagnosis of a malignant form is identical to the criteria used for thyroid carcinoma. Malignant SO is classified histopathologically into three types: papillary, follicular and the other variants of carcinoma [4].

Surgical resection remains the main primary treatment. In the case of benign SO, no complete further treatment other than the unilateral oophorectomy is necessary. Conservative surgery (cystectomy or oophorectomy) is recommended [8]. In the case of malignant SO, there is no standard consensus for its management. Many authors agree that due to the many similarities with thyroid cancer, it should be considered and managed as thyroid cancer (ovarian surgery, thyroidectomy and 131I radio-ablation) rather than ovarian cancer (ovarian surgery, radiotherapy and chemotherapy) [1, 2, 7]. The nature of the surgical procedure depends on the locoregional tumor extension and the patient’s age:

- Conservative surgery is reserved for younger patients seeking to preserve fertility if the disease is confined to the ovary, followed by definitive surgery after completion of childbearing [7, 9].
- Radical surgery, with TAH, bilateral salpingo-oophorectomy, peritoneal lymphadenectomy, thyroidectomy and radioablation with 131I should be reserved for more advanced disease and/or in postmenopausal patients [2, 4, 9].

The prognosis of benign struma is very favorable; however, that of malignant struma is poorly evaluated due to the limited number of published cases.

**AUTHORS’ CONTRIBUTIONS**

All the authors testified to the care of the patient and the writing of the manuscript. The authors have read and agreed with the contents of the manuscript.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**FUNDING**

None.

**CONSENT**

Written informed consent was obtained from the two patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

**REFERENCES**

1. Dardik RB, Dardik M, Westra W, Montz FJ. Malignant struma ovarii: two case reports and a review of the literature. Gynecol Oncol 1999;73:447–51.
2. Kunstmann L, Féniel P. Goitre ovarien: une forme particulière de tératome de l’ovaire [Struma ovarii, a rare form of ovarian tumor]. Gynécol Obstet Fert 2007;35:49–54.
3. Yoo SC, Chang KH, Lyu MO, Chang SJ, Ryu HS, Kim HS. Clinicopathologic study of 54 cases. Int J Gynecol Pathol 1993;12:333–43.
4. Joja I, Asakawa T, Mitsumori A, Nakagawa T, Hiraki Y, Kudo T, et al. Struma ovarii: appearance on MR images. Abdom Imaging 1998;23:652–6.
5. Devane S, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 1993;12:333–43.
6. Zakhem A, Aftimos G, Kreidy R, Salem F. Malignant struma ovarii: report of two cases and selected review of the literature. J Surg Oncol 1990;43:61–5.
8. Lamblin G, Gallice C, Bournaud C, Nadaud B, Lebail-Carval K, Chene G. Goîtres ovariens bénins: à propos de 7 cas et analyse de la littérature [Benign struma ovarii: report of 7 cases and review of the literature]. Gynecol Obstet Fertil 2016;44:263–8.

9. Vadmal MS, Smilari TF, Lovecchio JL, Klein IL, Hajdu SI. Diagnosis and treatment of disseminated struma ovarii with malignant transformation. Gynecol Oncol 1997;64:541–6.